Literature DB >> 21570273

Discrepancy between clinical criteria for diagnosing acute respiratory distress syndrome secondary to community acquired pneumonia with autopsy findings of diffuse alveolar damage.

Xavier Sarmiento1, Juan J Guardiola, Jordi Almirall, Eduard Mesalles, Jose Luis Mate, Manuel Soler, Jordi Klamburg.   

Abstract

Diffuse alveolar damage (DAD) is the underlying pathological finding in most cases of acute respiratory distress syndrome (ARDS). The objective of this study was to compare clinical criteria for ARDS secondary to community acquired pneumonia with autopsy findings of DAD and to determine the discrepancy rate between the two. We compared prospectively obtained clinical diagnosis of ARDS secondary to community acquired pneumonia with autopsy findings of DAD and pneumonia. Forty nine patients dead with a clinical diagnosis of ARDS secondary to pneumonia who underwent autopsy between 1986 and 2004 in our ICU were included with systematic histopathological analysis of all lung lobes. The discrepancy rate between the premortem clinical diagnosis of ARDS secondary to pneumonia and DAD at autopsy was determined. Seven patients were found to have neither infection nor DAD at autopsy. Six patients showed pathologic signs of DAD without evidence of infection. Out of 38 patients meeting clinical criteria for ARDS secondary to pneumonia and proven pneumonia at autopsy, 25 met criteria for DAD at autopsy. Therefore, 18 out of 49 patients who were clinically diagnosed with ARDS did not actually show pathological signs of DAD, resulting in a discrepancy rate of 37%. Despite an acceptable correspondence between clinical criteria for ARDS secondary to pneumonia and autopsy findings of DAD a significant number of patients had neither signs of DAD nor infection.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21570273     DOI: 10.1016/j.rmed.2011.04.001

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  6 in total

Review 1.  Acute pulmonary injury: high-resolution CT and histopathological spectrum.

Authors:  E T Obadina; J M Torrealba; J P Kanne
Journal:  Br J Radiol       Date:  2013-05-09       Impact factor: 3.039

2.  Acute respiratory distress syndrome in patients with and without diffuse alveolar damage: an autopsy study.

Authors:  José A Lorente; Pablo Cardinal-Fernández; Diego Muñoz; Fernando Frutos-Vivar; Arnaud W Thille; Carlos Jaramillo; Aida Ballén-Barragán; José M Rodríguez; Oscar Peñuelas; Guillermo Ortiz; José Blanco; Bruno Valle Pinheiro; Nicolás Nin; María del Carmen Marin; Andrés Esteban; Taylor B Thompson
Journal:  Intensive Care Med       Date:  2015-09-18       Impact factor: 17.440

3.  Acute respiratory distress syndrome: does histology matter?

Authors:  José A Lorente; Aida Ballén-Barragán; Raquel Herrero; Andrés Esteban
Journal:  Crit Care       Date:  2015-09-15       Impact factor: 9.097

4.  Clinical phenotypes from fatal cases of acute respiratory distress syndrome caused by pneumonia.

Authors:  Kazuya Ichikado; Kodai Kawamura; Takeshi Johkoh; Kiminori Fujimoto; Ayumi Shintani; Satoru Hashimoto; Yoshitomo Eguchi; Yuko Yasuda; Keisuke Anan; Naoki Shingu; Yoshihiko Sakata; Junpei Hisanaga; Tatsuya Nitawaki; Miwa Iio; Yuko Sekido; Kenta Nishiyama; Kazunori Nakamura; Moritaka Suga; Hidenori Ichiyasu; Takuro Sakagami
Journal:  Sci Rep       Date:  2021-10-08       Impact factor: 4.379

5.  Predictors of diffuse alveolar damage in patients with acute respiratory distress syndrome: a retrospective analysis of clinical autopsies.

Authors:  Arnaud W Thille; Oscar Peñuelas; José A Lorente; Pilar Fernández-Segoviano; José-Maria Rodriguez; José-Antonio Aramburu; Julian Panizo; Andres Esteban; Fernando Frutos-Vivar
Journal:  Crit Care       Date:  2017-10-20       Impact factor: 9.097

Review 6.  Extravascular lung water measurements in acute respiratory distress syndrome: why, how, and when?

Authors:  Takashi Tagami; Marcus Eng Hock Ong
Journal:  Curr Opin Crit Care       Date:  2018-06       Impact factor: 3.687

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.